SCHEMBL3520213

SCHEMBL3520213

COC(=O)c1c(OC)c(-c2ccc(F)c(F)c2)cc2nc(-c3cccs3)cnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ACLY P53396 1/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPT P10636 3/20 0.38
TNFRSF1A P19438 1/20 0.37
ATR Q13535 1/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HSD17B10 Q99714 2/20 0.37
TP53 P04637 2/20 0.37
USP2 O75604 1/20 0.37
F2 P00734 1/20 0.37
LMNA P02545 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520040 0.93 ACLY (0.41) MEN1KMT2AACLYNPC1RAB9A
SCHEMBL3520500 0.89 PDGFRB (0.40) MEN1KMT2ARAB9AHPGDPDGFRB
SCHEMBL3519874 0.88 MEN1 (0.49) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3518053 0.84 RPS6KB1 (0.39) MEN1KMT2AMAPTATRPDGFRB
SCHEMBL3524365 0.82 MEN1 (0.48) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3521378 0.82 PDGFRB (0.37) MEN1KMT2AACLYKDM4EPDGFRB
SCHEMBL3521337 0.82 MEN1 (0.47) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3518154 0.81 RXFP1 (0.41) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL3518253 0.78 PDGFRB (0.39) MEN1KMT2ARAB9AHPGDPDGFRB
SCHEMBL3520062 0.77 EGLN3 (0.49) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 MEN1 2552/4885KMT2A 300/4885ACLY 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.